Celadon Pharmaceuticals

AIM Rule 26

Aim Rule 26 Summary

This information has been disclosed pursuant to Rule 26 of the AIM Rules for Companies and was last updated on 28 March 2022.

Description of the Business

See link to Investor Overview section.

Name of the Directors and biographical details

See link to Board of Directors section.

Directors Responsibilities

See link to Board and Governance section.

Current Constitutional Documents

See link to Key Corporate Documents section.

Corporate Governance

The company complies with the QCA Corporate Governance Code.

For further details, please see link to Board and Governance section

Country of Incorporation / Operation

Celadon Pharmaceuticals Plc is incorporated in England and Wales and is listed solely on the London Stock Exchange Alternative Investment Market (AIM), and is subject to the UK City Code on Takeovers and Mergers.



There are no restrictions on the transfer of Celadon Pharmaceutical’s shares.

AIM securities in issue

The following information is correct as at 28 March 2022.

The Company’s issued share capital comprises 61,669,773 ordinary shares, each with a nominal value of 1 pence.

So far as the Company is aware, 70.6% of its issued share capital is not in public hands.

Significant shareholders

The Company has been notified of the following significant shareholders. Significant shareholders are those holding over 3% or more of the shares in issue.

NameNumber of ordinary shares heldPercentage holding of total issued share capital
James Short26,046,92842.2%
John Mitchell4,525,4037.3%
Paul Allen4,525,4037.3%
Cormac Short4,525,4037.3%
Jonathan Rickard2,251,3883.7%

Last updated: 27th March 2022

Director shareholdings

In aggregate, the Directors of the Company Hold 27,424,072 shares, representing 44.5 per cent of the issued share capital of the Company.

NameNumber of ordinary shares heldPercentage holding of total issued share capital
James Short (CEO)26,046,92842.2%
Alexander Anton (Chairman)1,319,5692.1%
Robert Barr (Senior Independant NED)45,4540.07%
David Firth (NED)12,1210.02%

Last updated: 27th March 2022

Financial Information

Company Announcements

See link to Regulatory News section

Admission Document